Can Novartis Reclaim Pioneering Role In Transplantation?

An Interview With Eric Hughes, Head Of Immunology, Hepatology and Dermatology At Novartis

Novartis is developing a new type of immunosuppressive agent, an anti-CD40 monoclonal antibody, which might allow organ transplants to last longer in recipients, reducing the pressure on transplant waiting lists and improving the long-term outlook for patients.

Pioneer
Novartis leads charge in development of a previously overlooked immunosuppressive process • Source: Shutterstock

Novartis AG might soon be able to reclaim some of the kudos it once received for developing groundbreaking transplant-enabling therapies like ciclosporin, through its pioneering of a new class of potential products now in early clinical development.

The Basel, Switzerland-based multinational has an impressive heritage in the organ transplant sector going back more than 30 years, but...

More from Market Intelligence

More from In Vivo

Rising Leaders 2025: Doxie Jordan, From UNC Graduate To Global Market Strategist

 
• By 

Bristol Myers Squibb executive Doxie Jordan discusses his path to global commercial leadership and the principles guiding pharmaceutical market strategy

Podcast: Brain+ CEO Discusses “Groundbreaking” Potential Of CST Assistant For Dementia Patients

 

Devika Wood, CEO of Brain+, explains the importance of developing health tech solutions for dementia and the growing need to both raise awareness and improve overall access to nondrug interventions like CST.

Behind The Buyout: Dispatches From The Dealmaking Table

 
• By 

In a challenging funding environment for biopharma, strategic dealmaking has become a critical growth engine. In Vivo explores what it truly takes to navigate high-stakes acquisitions and partnerships, drawing on insights from seasoned industry leaders.